Publications by authors named "E Charton"
Article Synopsis
- * Results show significant differences in the microstructure and proteolysis rates of HM and IF, with IF being digested faster than HM, especially in the stomach and early intestine.
- * The findings indicate a strong correlation between in vitro and in vivo digestion outcomes, suggesting that in vitro models can effectively mimic the digestive process of HM in a living organism.
Introduction: This study assessed the influence of intrapersonal (one's own emotions) and interpersonal (emotions of others) emotional competence (EC) of informal caregivers on their quality of life (QoL) at the beginning of cancer care.
Methods: Participants completed two questionnaires assessing their intrapersonal and interpersonal EC (S-PEC) as well as their QoL (SF-36) at the beginning of treatments. Multivariate ANCOVA regression analyses were then performed to explore the influence of EC on QoL.
SUNLAND: a randomized, double-blinded phase II GERCOR trial of sunitinib versus placebo and lanreotide in patients with advanced progressive midgut neuroendocrine tumors.
Ther Adv Med Oncol
November 2024
Background: Sunitinib, a multitarget tyrosine kinase inhibitor, showed encouraging antitumor activity and manageable toxicity in patients with advanced midgut neuroendocrine tumors (NETs) in earlier results from phase I and II trials.
Patients And Methods: In this phase II trial, patients with a nonresectable grade 1 or 2 midgut progressive NET and Eastern Cooperative Oncology Group performance status 0-1 were randomly assigned 1:1 to receive 37.5 mg sunitinib or a placebo, combined with 120 mg lanreotide autogel every 28 days.
Article Synopsis
- Advances in lymphoma treatment have made assessing health-related quality of life (HRQoL) crucial for newly diagnosed patients, yet there's limited information on their HRQoL profiles at diagnosis.
- A study involving 3922 adults with various lymphoma types utilized three validated EORTC questionnaires to evaluate HRQoL at diagnosis, achieving high completion rates between 84% and 88%.
- Findings highlighted significant impairments in global health status across lymphoma subtypes, with factors like gender, performance status, and B symptoms affecting HRQoL, providing valuable insights for future research and clinical practices.
Chimeric antigen receptor T cells (CAR T cells) can induce prolonged remission in a substantial subset of patients with relapse/refractory lymphoma. However, little is known about patients' life after CAR T-cell therapy. We prospectively assessed the multidimensional recovery of lymphoma patients in remission, before leukapheresis, before CAR T-cell infusion, and 3, 6, and 12 months thereafter.
View Article and Find Full Text PDF